Pattern of cytokines and pharmacomodulation in sepsis induced by cecal ligation and puncture compared with that induced by endotoxin

The production of tumor necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and IL-6 and their pharmacomodulation were evaluated in a model of polymicrobial sepsis induced in mice by cecal ligation and puncture (CLP) and were compared with the effects of endotoxin (lipopolysaccharide [LPS]) treatment. LPS levels rose as early as 1 h after CLP and increased further after 2 and 21 h. TNF-alpha was detectable in serum, spleen, liver, and lungs during the first 4 h, with a peak 2 h after CLP. IL-1 beta was measurable in serum after 24 h, and levels increased significantly in spleen and liver 4 and 8 h after CLP. IL-6 levels increased significantly in serum throughout the first 16 h after CLP. These cytokines were detectable after LPS injection, with kinetics similar to those after CLP but at a significantly higher level. To cast more light on the differences between these two animal models of septic shock, we studied the effects of different reference drugs. Pretreatment with dexamethasone (DEX); ibuprofen (IBU), an inhibitor of cyclooxygenase; and NG-nitro-L-arginine, an inhibitor of nitric oxide synthase, significantly reduced survival, while chlorpromazine (CPZ) and TNF did not affect it. Only the antibiotics and pentoxifylline significantly increased survival in mice with CLP. However, CPZ and DEX protected the mice from LPS mortality. On inhibiting TNF-alpha with DEX, CPZ, or pentoxifylline, survival was reduced, unchanged, and increased, respectively, and on increasing TNF-alpha with IBU and TNF, survival was decreased or unchanged, respectively, suggesting that the modulation of this cytokine does not play a significant role in sepsis induced by CLP, unlike treatment with LPS. The negative effects of IBU and N(G)-nitro-L-arginine suggest a protective role by prostaglandins and nitric oxide in sepsis induced by CLP.

[1]  Andrew N. Rowan.  Guide for the Care and Use of Laboratory Animals , 1996 .

[2]  D. Gouma,et al.  LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. , 1993, Journal of immunology.

[3]  G. Grau,et al.  Stabilisation of functional tumor necrosis factor-alpha by its soluble TNF receptors. , 1993, European cytokine network.

[4]  T. van der Poll,et al.  Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. , 1993, Journal of immunology.

[5]  G. Babcock,et al.  Prostaglandin E1 analogues misoprostol and enisoprost decrease microbial translocation and modulate the immune response. , 1993, Circulatory shock.

[6]  J. Alexander,et al.  Arginine‐Supplemented Diets Improve Survival in Gut‐Derived Sepsis and Peritonitis by Modulating Bacterial Clearance The Role of Nitric Oxide , 1993, Annals of surgery.

[7]  G. Matuschak,et al.  TNF-alpha and cyclooxygenase metabolites do not modulate C. albicans septic shock with disseminated candidiasis. , 1993, Journal of applied physiology.

[8]  G. Matuschak,et al.  Effects of pentoxifylline on tumor necrosis factor production and survival during lethal E. coli sepsis vs. disseminated candidiasis with fungal septic shock. , 1993, Circulatory shock.

[9]  P. Gnocchi,et al.  Development and applications of a radioimmunoassay (RIA) for the in vitro and in vivo quantification of murine IL-1 beta. , 1992, Lymphokine and cytokine research.

[10]  C. Natanson,et al.  N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin , 1992, The Journal of experimental medicine.

[11]  A. Mantovani,et al.  Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. , 1992, International journal of immunopharmacology.

[12]  J. Norton,et al.  Recombinant interleukin-1 receptor antagonist (IL-1ra): effective therapy against gram-negative sepsis in rats. , 1992, Surgery.

[13]  D. Remick,et al.  Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. , 1992, Journal of immunology.

[14]  J. Cavaillon,et al.  Dissociation between plasma and monocyte‐associated cytokines during sepsis , 1991, European journal of immunology.

[15]  H. Langstein,et al.  Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. , 1991, The Journal of clinical investigation.

[16]  A. Mantovani,et al.  Protective effect of chlorpromazine on endotoxin toxicity and TNF production in glucocorticoid-sensitive and glucocorticoid-resistant models of endotoxic shock , 1991, The Journal of experimental medicine.

[17]  P. Kubes,et al.  Nitric oxide: an endogenous modulator of leukocyte adhesion. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  B. Echtenacher,et al.  Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.

[19]  U. Gullberg,et al.  Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. , 1990, The Journal of clinical investigation.

[20]  B. Schleiffenbaum,et al.  The tumor necrosis factor receptor and human neutrophil function. Deactivation and cross-deactivation of tumor necrosis factor-induced neutrophil responses by receptor down-regulation. , 1990, The Journal of clinical investigation.

[21]  P. Krause,et al.  Pentoxifylline-induced modulation of human leukocyte function in vitro. , 1990, The American journal of pathology.

[22]  P. Ghezzi,et al.  Protective effect of chlorpromazine against the lethality of interleukin 1 in adrenalectomized or actinomycin D-sensitized mice. , 1989, Biochemical and biophysical research communications.

[23]  S. Zuckerman,et al.  Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. , 1989, Circulatory shock.

[24]  E. Hofsli,et al.  A flow cytometric and immunofluorescence microscopic study of tumor necrosis factor production and localization in human monocytes. , 1989, Cellular immunology.

[25]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[26]  G. Chalkiadakis,et al.  Pentoxifylline in the treatment of experimental peritonitis in rats. , 1985, Archives of surgery.

[27]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[28]  I. Chaudry,et al.  Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. , 1983, Surgery.

[29]  S. Tannenbaum,et al.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. , 1982, Analytical biochemistry.

[30]  P. Halushka,et al.  Ibuprofen improves survival from endotoxic shock in the rat. , 1980, Journal of Pharmacology and Experimental Therapeutics.

[31]  I. Chaudry,et al.  Sepsis and septic shock--a review of laboratory models and a proposal. , 1980, The Journal of surgical research.

[32]  G. Fantuzzi,et al.  Chlorpromazine specifically inhibits peripheral and brain TNF production, and up-regulates IL-10 production, in mice. , 1994, Immunology.

[33]  P. Ghezzi,et al.  Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock. , 1993, European cytokine network.

[34]  N. Hiraoka,et al.  Inhibitory effect of pentoxifylline and prostaglandin E1 on the release of neutrophil elastase from FMLP-stimulated neutrophils. , 1991, Journal of medicine.

[35]  G. Bagby,et al.  Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. , 1990, Life sciences.